

federally listed species present was not economically feasible.

John E. Cross,

*Acting Regional Director, Region 2,
Albuquerque, New Mexico.*

[FR Doc. 95-11352 Filed 5-8-95; 8:45 am]

BILLING CODE 4510-55-M

**INTERSTATE COMMERCE
COMMISSION**

[Docket No. AB-167 (Sub-No. 1145X)]

**Consolidated Rail Corporation—
Abandonment Exemption—
Philadelphia, PA**

AGENCY: Interstate Commerce Commission.

ACTION: Notice of exemption.

SUMMARY: Under 49 U.S.C. 10505, the Commission exempts from the prior approval requirements of 49 U.S.C. 10903-10904 the abandonment by Consolidated Rail Corporation (Conrail) of the 1.64-mile "City Branch", between milepost 0.66 at the east side of Broad Street, and milepost 2.3 at the east side of 30th Street, in Philadelphia, Philadelphia County, PA. The exemption is subject to trail use, public use, historic preservation, and labor protective conditions.

DATES: The exemption will be effective May 26, 1995, unless stayed or a statement of intent to file an offer of financial assistance (OFA) is filed. Statements of intent to file an OFA under 49 CFR 1152.27(c)(2), requests for a notice of interim trail use/rail banking under 49 CFR 1152.29, petitions to stay, requests for a public use condition under 49 CFR 1152.28, and petitions to reopen must be filed by May 22, 1995.

ADDRESSES: An original and 10 copies of all pleadings, referring to Docket No. AB-167 (Sub-No. 1145X), must be filed with the Office of the Secretary, Case Control Branch, Interstate Commerce Commission, 1201 Constitution Avenue, NW., Washington, DC 20423. In addition, a copy of all pleadings must be served on John J. Paylor, Consolidated Rail Corporation, 2001 Market Street, 16A, Philadelphia, PA 19101.

FOR FURTHER INFORMATION CONTACT: Joseph H. Dettmar, (202) 927-5660. [TDD for the hearing impaired: (202) 927-5721.]

SUPPLEMENTARY INFORMATION: Additional information is contained in the Commission's decision. To purchase a copy of the decision, write to, call or pick up in person from Dynamic Concepts, Inc., Interstate Commerce Commission Building, 1201 Constitution Avenue, N.W., Room 2229, Washington, DC 20423. Telephone: (202) 289-4357/4359. [Assistance for the hearing-impaired is available through TDD services at (202) 927-5721.]

Decided: May 1, 1995.

By the Commission, Chairman Morgan, Vice Chairman Owen, and Commissioners Simmons and McDonald.

Vernon A. Williams,

Secretary.

[FR Doc. 95-11363 Filed 5-8-95; 8:45 am]

BILLING CODE 7035-01-M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[DEA No. 132P]

**Controlled Substances: Proposed 1995
Aggregate Production Quotas**

AGENCY: Drug Enforcement Administration.

ACTION: Notice of proposed revised aggregate production quotas for 1995.

SUMMARY: This notice proposes revised 1995 aggregate production quotas for controlled substances in Schedules I and II, as required under the Controlled Substances Act of 1970.

DATES: Comments or objections should be received on or before June 8, 1995.

ADDRESSES: Send comments or objections to the Administrator, Drug Enforcement Administration, Washington, DC 20537, Attn: DEA Federal Register Representative/CCR.

FOR FURTHER INFORMATION CONTACT: Howard McClain, Jr., Chief, Drug & Chemical Evaluation Section, Drug

Enforcement Administration, Washington, DC 20537, Telephone: (202) 307-7183.

SUPPLEMENTARY INFORMATION: Section 306 of the Controlled Substances Act (CSA) (21 U.S.C. 826) requires that the Attorney General establish aggregate production quotas for all controlled substances listed in Schedules I and II. This responsibility has been delegated to the Administrator of the DEA pursuant to § 0.100 of Title 28 of the Code of Federal Regulations.

The Administrator, in turn, has redelegated this function to the Deputy Administrator of the DEA by § 0.104 of Title 28 of the Code of Federal Regulations.

On October 20, 1994, a notice of the 1995 established aggregate production quotas was published in the **Federal Register** (59 FR 52991). The notice stipulated that the Deputy Administrator of the DEA would adjust the quotas in early 1995 as provided for in Title 21, Code of Federal Regulations, § 1303.23(c). These aggregate production quotas represent those amounts of controlled substances that may be produced in the United States in 1995 and do not include amounts which may be imported for use in industrial processes.

The proposed revisions are based on a review of 1994 year-end inventories, 1994 disposition data submitted by quota applicants, estimates of the medical needs of the United States submitted to the DEA by the Food and Drug Administration and other information available to the DEA.

Therefore, under the authority vested in the Attorney General by section 306 of the CSA of 1970 (21 U.S.C. 826), delegated to the Administrator by § 0.100 of Title 28 of the Code of Federal Regulations, and redelegated to the Deputy Administrator by § 0.104 of Title 28 of the Code of Federal Regulations, the Deputy Administrator of the DEA hereby proposes the following changes in the 1995 aggregate production quotas for the listed controlled substances, expressed in grams of anhydrous acid or base.

Basic class	Previously established 1995 aggregate production quotas	Proposed revised 1995 aggregate production quotas
Schedule I:		
Acetylmethadol	2	7
Alphacetylmethadol	0	5
Aminorex	2	7
Bufotenine	10	10
Cathinone	4	9
Difenoxin	14,000	14,000

Basic class	Previously established 1995 aggregate production quotas	Proposed revised 1995 aggregate production quotas
Dihydromorphine	0	5
2,5-Dimethylamphetamine	15,650,000	15,650,000
Dimethylamphetamine	2	7
Ethylamine analog of Phencyclidine	0	5
N-Ethylamphetamine	4	9
Lysergic acid diethylamide	41	56
Mescaline	2	7
Methaqualone	2	7
Methcathinone	9	14
4-Methoxyamphetamine	12	17
4-Methylaminorex	2	2
3,4-Methylenedioxyamphetamine	12	17
3,4-Methylenedioxy-N-ethylamphetamine	2	27
3,4-Methylenedioxymethamphetamine	12	17
3-Methylfentanyl	12	14
Normethadone	0	5
Normorphine	2	7
Tetrahydrocannabinols	35,000	35,000
Thiophene Analog of Phencyclidine	10	10
Schedule II:		
Alfentanil	7,000	7,000
Amobarbital	5	15
Amphetamine	1,026,100	1,026,100
Cocaine	550,000	550,000
Codeine (for sale)	67,312,000	67,312,000
Codeine (for conversion)	16,181,000	16,181,000
Desoxyephedrine	900,000	1,154,000
(1,138,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product and 16,000 grams for methamphetamine)		
Dextropropoxyphene	124,012,000	124,012,000
Dihydrocodeine	202,000	100,000
Diphenoxylate	688,000	346,000
Ecgonine (for conversion)	650,000	650,000
Ethylmorphine	0	10
Fentanyl	76,000	52,000
Hydrocodone	8,474,000	8,474,000
Hydromorphone	404,000	404,000
Isomethadone	0	10
Levo-alpha-acetylmethadol	200,000	200,000
Levorphanol	8,000	8,000
Meperidine	8,637,000	9,521,000
Methadone	3,779,000	3,779,000
Methadone (for conv)	364,000	364,000
Methadone Intermediate (for sale)	300,000	0
Methadone Int. (for conv)	4,393,000	4,393,000
Methylphenidate	8,886,000	10,410,000
Morphine (for sale)	7,612,000	7,612,000
Morphine (for conv)	78,105,000	78,105,000
Noroxymorphone (for sale)	21,000	21,000
Noroxymorphone (for conv)	3,500,000	3,500,000
Opium	1,118,000	1,304,000
Oxycodone (for sale)	3,613,000	4,254,000
Oxycodone (for conv)	23,000	25,500
Oxymorphone	9,200	10,200
Pentobarbital	15,706,000	15,706,000
Phencyclidine	52	72
Phenylacetone (for conv)	3,528,000	3,528,000
1-Phenylcyclohexylamine	0	10
1-Piperidinocyclohexanecarbonitrile	0	10
Secobarbital	480,000	322,000
Sufentanil	1,600	1,600
Thebaine	9,383,000	9,383,000

All interested persons are invited to submit their comments and objections in writing regarding this proposal. A person may object to or comment on the proposal relating to any of the above mentioned substances without filing

comments or objections regarding the others. If a person believes that one or more of these issues warrant a hearing, the individual should so state and summarize the reasons for this belief.

In the event that comments or objections to this proposal raise one or more issues which the Deputy Administrator finds warrant a hearing, the Deputy Administrator shall order a public hearing by notice in the **Federal**

Register, summarizing the issues to be heard and setting the time for the hearing.

The Office of Management and budget has determined that notice of aggregate production quotas are not subject to centralized review under Executive Order 12866.

Rules establishing aggregate production quotas for controlled substances in Schedules I and II are required by statute, fulfill United States obligations under the Single Convention on Narcotic Drugs, 1961, and other international treaties, and are essential to a criminal law enforcement function of the United States. Without the periodic establishment and adjustment of aggregate production quotas, pharmaceutical manufacturers in the United States could not lawfully produce a wide variety of medically necessary pharmaceutical drugs.

These actions have been analyzed in accordance with the principles and criteria contained in Executive Order 12612 and it has been determined that this matter raises no Federalism implications which would warrant the preparation of a Federalism Assessment.

The Deputy Administrator hereby certifies that this action will have no significant impact upon small entities whose interests must be considered under the Regulatory Flexibility Act, 5 U.S.C. 601, et seq. The establishment and revision of annual production quotas for Schedules I and II controlled substances is mandated by law and by the international obligations of the United States. Such quotas impact predominantly upon major

manufacturers of the affected controlled substances.

Dated: May 3, 1995.

Stephen H. Greene,

Deputy Administrator.

[FR Doc. 95-11370 Filed 5-8-95; 8:45 am]

BILLING CODE 4410-09-M

DEPARTMENT OF LABOR

Office of the Secretary

Surveys of the Federal Family and Medical Leave Act

AGENCY: Office of the Secretary, Labor.

SUMMARY: The Director, Office of Information Resources Management Policy, invites comments on the following proposed expedited review information collection request as required by the Paperwork Reduction Act of 1980, as amended.

DATES: This expedited review is being requested in accordance with the Act, since allowing for the normal review period would adversely affect the public interest. Approval by the Office of Management and Budget (OMB) has been requested by May 26, 1995.

ADDRESSES: Written comments should be addressed to the Office of Management and Budget (OMB) Office of Information and Regulatory Affairs, Attention: Dan Chenok, Desk Officer, 725 17th St., NW., Room 10235, New Executive Office Building, Wash., DC 20503. Requests for copies of the proposed information collection request should be addressed to Kenneth A.

Mills, Department of Labor, 200 Constitution Ave., NW Room N-1301, Wash., DC 20210.

FOR FURTHER INFORMATION CONTACT: Kenneth A. Mills, (202) 219-5095.

Individuals who use a telecommunications device for the deaf (TTY/TDY) may call (202) 219-4720 between 1:00 p.m. and 4:00 p.m. Eastern time, Monday through Friday.

SUPPLEMENTARY INFORMATION: Section 3517 of the Paperwork Reduction Act of 1980 (44 U.S.C. Chapter 3517) requires that the Director of OMB provide interested persons an early opportunity to comment on information collection requests. OMB may amend or waive the requirement for public consultation to the extent that public participation in the approval process would defeat the purpose of the information collection, violate State or Federal law, or substantially interfere with the agency's ability to perform its statutory obligations.

The Director, Office of Information Resource Management Policy, publishes this notice simultaneously with the submission of this request to OMB. This notice contains the following information:

Type of Review: EXPEDITED

Title: Commission on Leave Survey of Businesses on the Impact of the Federal Family and Medical Leave Act (and an embedded study of employees)

Frequency of Response: One-time Affected Public: Individuals or households; Business or other for-profit

Survey	Respondents	Average time per response	Total hours
Employer	1,200	65 minutes	1,300
Case Studies	6	4 hours	24
Employee	400	10 minutes	67

Total Annual Burden Hours: 1,391

Respondents obligation to reply:

Voluntary

Description: Title III of the Federal Family and Medical Leave Act of 1993 (FMLA) established a bipartisan Commission on Leave (the Commission) to conduct a comprehensive study and to submit a report to Congress on mandatory and voluntary policies relating to family leave and temporary medical leave.

The Commission is to conduct a comprehensive study and to report its findings to Congress not later than two years after the date the Commission first met which was held on November 10, 1993.

The Commission plans to survey a random sample of employers who are covered and not covered by the provisions of the FMLA and a sample of employees who are covered and not covered by the provisions of the FMLA

and who have taken family and medical leave. The data collected will be used primarily for reporting to the Congress in the Final report due November 1995.

Type of Review: EXPEDITED

Title: Commission on Leave Survey of Employee on the Impact of the Federal Family and Medical Leave Act

Frequency of Response: One-time Affected Public: Individuals or households